:strip_icc()/i.s3.glbimg.com/v1/AUTH_59edd422c0c84a879bd37670ae4f538a/internal_photos/bs/2024/Q/t/fOczghSryAGQezEAqd2w/mg2-acervo-12-07-2024-7-frame-109497.jpeg "The National Vaccine Center is scheduled to start operating in 2026; “It will be the main research center in the region,” says Science Minister | Minas Gerais")
The research complex is located in the Belo Horizonte Technological Park (BH-TEC) and is a partnership between the Federal University of Minas Gerais (UFMG), the Ministry of Science, Technology and Innovation, which invested R$50 million in the unit, and the State of Minas Gerais, which invested another R$30 million.
Minister Luciana Santos visited space on Friday (12)..
“Without a doubt, it will be the main center for vaccine research and development in Brazil, and we will make this a continuous flow of investments so that this segmental treatment is delivered to the Brazilian population within the next two years,” the minister said.
The National Vaccine Center began work at the end of 2022. The difference for a vaccine manufacturer, such as the Butantan Institute, for example, is that It will be able to combine all stages of vaccine development, from conception to human testing..
“This is the mission of this center: to take the research that people are doing at universities and bring it to our center. Develop and make a prototype of a vaccine approved by Anvisa and then take it to the clinical trial. Phase I. Phase II, and eventually Phase III,” explained the coordinator of the Vaccine Technology Center (CT Vacinas) at UFMG, Riccardo Gazzinelli.
According to him, The building is expected to be ready by the end of 2025 and to start operating in mid-2026..
The project envisions that the structure will have: Five floors with an area of approximately 6 thousand square metersIn addition to research and laboratory areas, the center will include an area for receiving patients and outpatient clinics for conducting clinical tests.
Brazilian Covid Vaccine
Near the construction site of the National Vaccine Center is the UFMG CT Vacinas, where SpiN-TEC, the first 100% Brazilian vaccine against Covid-19, is being developed.
“We see from the results that we actually have a response as good as the enhanced response with AstraZeneca, for example. So, what's happening now is that Anvisa is analyzing these results,” said CT Vacinas deputy coordinator Santoza Teixeira.
Most viewed videos on g1 Minas:
Andrea Hargraves is a contributor to Brytfmonline.com, covering a broad range of topics including news, politics, business, technology, sports, entertainment, and lifestyle. She is committed to delivering clear, accurate, and reader-focused reporting that helps audiences stay informed about current events and emerging developments. Andrea’s work emphasizes useful information, balanced coverage, and stories that matter to everyday readers, making complex topics accessible and relevant to a wide audience.